# LENSAR, Inc.: overview LNSR · Nasdaq · CIK 1320350 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lnsr.md) · [Financials](/companies/lnsr/financials.md) · [Filings](/companies/lnsr/filings.md) · [Insiders](/companies/lnsr/insiders.md) Latest reported revenue: [$14.7m](/filings/0001193125-26-349315.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-349315). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.8](/filings/0001193125-25-269428.md) | [14.8 d](/filings/0001193125-26-134587.md) | [12.3](/filings/0001193125-26-214571.md) | [12.3](/filings/0001193125-26-349315.md) | [12.8](/filings/0001193125-25-269428.md) | [14.3 d](/filings/0001193125-26-134587.md) | [11.7](/filings/0001193125-26-214571.md) | [14.7](/filings/0001193125-26-349315.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(10.5%)](/filings/0001193125-25-269428.md) | [(8.7%) d](/filings/0001193125-26-134587.md) | [(47.2%)](/filings/0001193125-26-214571.md) | [(51.2%)](/filings/0001193125-26-349315.md) | [(59.4%)](/filings/0001193125-25-269428.md) | [(34.3%) d](/filings/0001193125-26-134587.md) | [19.1%](/filings/0001193125-26-214571.md) | [14.5%](/filings/0001193125-26-349315.md) | | Net margin | % | [(12.7%)](/filings/0001193125-25-269428.md) | [(126.2%) d](/filings/0001193125-26-134587.md) | [(222.8%)](/filings/0001193125-26-349315.md) | [(14.4%)](/filings/0001193125-26-349315.md) | [(29.1%)](/filings/0001193125-25-269428.md) | [(10.2%) d](/filings/0001193125-26-134587.md) | [309.3%](/filings/0001193125-26-349315.md) | [24.0%](/filings/0001193125-26-349315.md) | | Diluted EPS | $ per share | [(0.13)](/filings/0001193125-25-269428.md) | not reported | [(2.32)](/filings/0001193125-26-214571.md) | [(0.15)](/filings/0001193125-26-349315.md) | [(0.31)](/filings/0001193125-25-269428.md) | not reported | [0.00](/filings/0001193125-26-214571.md) | [0.10](/filings/0001193125-26-349315.md) | | Free cash flow | $m | [3.1 d](/filings/0001193125-25-269428.md) | [3.7 d](/filings/0001193125-26-134587.md) | [(6.9)](/filings/0001193125-26-214571.md) | [(5.1) d](/filings/0001193125-26-349315.md) | [(3.5) d](/filings/0001193125-25-269428.md) | [0.6 d](/filings/0001193125-26-134587.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [29.5](/filings/0000950170-23-008513.md) | [29.4](/filings/0000950170-24-024807.md) | [35.7](/filings/0000950170-25-029003.md) | [46.0](/filings/0001193125-26-134587.md) | [51.7](/filings/0001193125-26-134587.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(66.6%)](/filings/0000950170-23-008513.md) | [(68.5%)](/filings/0000950170-24-024807.md) | [(34.2%)](/filings/0000950170-25-029003.md) | [(23.2%)](/filings/0001193125-26-134587.md) | [(47.6%)](/filings/0001193125-26-134587.md) | | Net margin | % | [(66.5%)](/filings/0000950170-23-008513.md) | [(67.6%)](/filings/0000950170-24-024807.md) | [(40.3%)](/filings/0000950170-25-029003.md) | [(68.3%)](/filings/0001193125-26-134587.md) | [(66.4%)](/filings/0001193125-26-134587.md) | | Diluted EPS | $ per share | [(2.09)](/filings/0000950170-23-008513.md) | [(1.96)](/filings/0000950170-24-024807.md) | [(1.31)](/filings/0000950170-25-029003.md) | [(2.73)](/filings/0001193125-26-134587.md) | [(2.87)](/filings/0001193125-26-134587.md) | | Free cash flow | $m | [(9.3)](/filings/0000950170-23-008513.md) | [(15.0)](/filings/0000950170-24-024807.md) | [(9.9)](/filings/0000950170-25-029003.md) | [(2.4)](/filings/0001193125-26-134587.md) | [(14.9)](/filings/0001193125-26-134587.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lnsr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BRANDES INVESTMENT PARTNERS, LP](/funds/1015079.md) | 2026-06-30 | $6.1m | 1,075,400 | | Added +50,224 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.3m | 402,806 | | Added +12,716 | | [Groupe la Francaise](/funds/2056088.md) | 2026-06-30 | $1.2m | 213,537 | | Unchanged | | [RBF Capital, LLC](/funds/1134621.md) | 2026-06-30 | $1.1m | 188,661 | | Added +143,134 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.1m | 185,033 | | Reduced −443,715 | | [CSS LLC/IL](/funds/1103646.md) | 2026-06-30 | $933.3k | 163,450 | | Unchanged | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $865.7k | 151,609 | | Reduced −73,325 | | [CREDIT INDUSTRIEL ET COMMERCIAL](/funds/1274419.md) | 2026-06-30 | $824.3k | 144,359 | | Unchanged | | [Kerrisdale Advisers, LLC](/funds/1569688.md) | 2026-06-30 | $795.9k | 139,390 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $689.1k | 120,680 | | Added +108,115 | ## Recent filings [All 317 filings](/companies/lnsr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 16:30 ET | [10-Q](/filings/0001193125-26-349315.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349315 | | 2026-08-13 | 07:10 ET | [8-K](/filings/0001193125-26-347859.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-347859 | | 2026-08-10 | 16:05 ET | [8-K](/filings/0001193125-26-342330.md) | 5.07 Shareholder vote results | 0001193125-26-342330 | | 2026-06-23 | 16:20 ET | [DEF 14A](/filings/0001193125-26-279484.md) | Proxy statement, period 2026-06-23 | 0001193125-26-279484 | | 2026-05-29 | 16:05 ET | [8-K](/filings/0001193125-26-248230.md) | 5.02 Departure or appointment of officers or directors; 5.08 Item not in the standard list; 8.01 Other events | 0001193125-26-248230 | | 2026-05-08 | 16:00 ET | [10-Q](/filings/0001193125-26-214571.md) | Quarterly report, period 2026-03-31 | 0001193125-26-214571 | | 2026-05-08 | 07:05 ET | [8-K](/filings/0001193125-26-213268.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-213268 | | 2026-04-30 | 16:30 ET | [10-K/A](/filings/0001193125-26-197477.md) | Annual report, amended, period 2025-12-31 | 0001193125-26-197477 | | 2026-04-15 | 16:30 ET | [8-K](/filings/0001193125-26-157105.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-157105 | | 2026-03-31 | 16:14 ET | [10-K](/filings/0001193125-26-134587.md) | Annual report, period 2025-12-31 | 0001193125-26-134587 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-134587.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/deb4fbe0-6479-4c83-bdf2-b24220e13d87) ## About the filer - CIK: 1320350 - Tickers: LNSR - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.